NIAID (National Institute of Allergy and Infectious Diseases)
Scientific/Medical Group Awards
HPTN 083 & HPTN 084 Clinical Trial Team
In recognition of exceptional conduct of the HPTN 083 & HPTN 084 clinical trials that resulted in FDA approval of Cabotegravir Long Acting (CAB LA).
NIAID Accelerating COVID-19 Therapeutic Interventions and Vaccines Team
For outstanding efforts to develop and implement the ACTIV-2 trial (Outpatient Monoclonal Antibodies and Other Therapies).